J. Ashley Jefferson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
J. Ashley Jefferson has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Abbal Koirala
Johns Hopkins University School of Medicine
3 shared publications Stuart J. Shankland
Division of Nephrology, Department of Medicine, University of Washington, Seattle, WA
2 shared publicationsCharles E. Alpers
1 shared publication- Shreeram Akilesh
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195
1 shared publication - Syeda Behjat Ahmad
Division of Nephrology, University of Washington, Seattle, Washington, USA
1 shared publication
Latest Publications
- 4 June 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1844-1857
Targeting B Cells and Plasma Cells in Glomerular Disease
Loss of tolerance and the production of self-reactive autoantibodies by the humoral immune system are central to the pathogenesis of many glomerular diseases. These antibodies are produced by plasmablasts and plasma cells, the end products of B-cell lineage development within the bone marrow and secondary lymphoid tissues. In addition to antibody production, B cells also present antigen to T cells and produce proinflammatory cytokines. Nontargeted immunosuppression has shown efficacy in glomerular disease but is associated with multiple side effects, and there remains a high proportion of patients with resistant disease. In this article, we will review the biology of antibody-secreting cells and focus on therapeutics that specifically target B cells and plasma cells. We will review B-cell depletion strategies, including anti-CD20 monoclonal antibodies, B-cell–activating factor, and a proliferation-inducing ligand inhibition and B-cell receptor inhibition, highlighting their role in different glomerular diseases and outlining reasons for therapeutic resistance. We will also review plasma cell–directed therapies including proteasome inhibition and anti-CD38 therapies and discuss novel treatments including chimeric antigen receptor-T therapy and bispecific T-cell engagers.
- 4 June 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (9) , 1844-1857
Targeting B Cells and Plasma Cells in Glomerular Disease
Loss of tolerance and the production of self-reactive autoantibodies by the humoral immune system are central to the pathogenesis of many glomerular diseases. These antibodies are produced by plasmablasts and plasma cells, the end products of B-cell lineage development within the bone marrow and secondary lymphoid tissues. In addition to antibody production, B cells also present antigen to T cells and produce proinflammatory cytokines. Nontargeted immunosuppression has shown efficacy in glomerular disease but is associated with multiple side effects, and there remains a high proportion of patients with resistant disease. In this article, we will review the biology of antibody-secreting cells and focus on therapeutics that specifically target B cells and plasma cells. We will review B-cell depletion strategies, including anti-CD20 monoclonal antibodies, B-cell–activating factor, and a proliferation-inducing ligand inhibition and B-cell receptor inhibition, highlighting their role in different glomerular diseases and outlining reasons for therapeutic resistance. We will also review plasma cell–directed therapies including proteasome inhibition and anti-CD38 therapies and discuss novel treatments including chimeric antigen receptor-T therapy and bispecific T-cell engagers.
- 29 July 2024
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 31 (4) , 290-298
Collapsing Glomerulopathy
- 29 July 2024
- Published by Elsevier in Advances in Kidney Disease and Health
- Vol. 31 (4) , 290-298
Collapsing Glomerulopathy
- Open Access
- 29 July 2021
- Published by S. Karger AG in Glomerular Diseases
- Vol. 1 (4) , 237-249
Steroid Minimization in Adults with Minimal Change Disease
Background: Minimal change disease (MCD) causes approximately 10% of nephrotic syndrome in adults. While glucocorticoids (GCs) effectively induce remission in MCD, the disease has a high relapse rate (50–75%), and repeated exposure to GCs is often required. The adverse effects of GCs are well recognized and commonly encountered with the high doses and recurrent courses used in MCD. Summary: In this review, we will discuss the standard therapy of MCD in adults and then describe new therapeutic options in induction therapy and treatment of relapses in MCD, minimizing the exposure to GCs. Key Messages: Steroid minimization strategies may decrease adverse effects in the treatment of MCD.
- 29 July 2021
- Published by S. Karger AG in Glomerular Diseases
- Vol. 1 (4) , 237-249
Open AccessSteroid Minimization in Adults with Minimal Change Disease
Background: Minimal change disease (MCD) causes approximately 10% of nephrotic syndrome in adults. While glucocorticoids (GCs) effectively induce remission in MCD, the disease has a high relapse rate (50–75%), and repeated exposure to GCs is often required. The adverse effects of GCs are well recognized and commonly encountered with the high doses and recurrent courses used in MCD. Summary: In this review, we will discuss the standard therapy of MCD in adults and then describe new therapeutic options in induction therapy and treatment of relapses in MCD, minimizing the exposure to GCs. Key Messages: Steroid minimization strategies may decrease adverse effects in the treatment of MCD.
- 15 October 2020
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 15 (11) , 1541-1542
How Safe Is a Native Kidney Biopsy?
- 15 October 2020
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 15 (11) , 1541-1542
How Safe Is a Native Kidney Biopsy?
- 24 July 2018
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 13 (8) , 1264-1275
Complications of Immunosuppression in Glomerular Disease
Most glomerular diseases are immunologically mediated disorders of the kidney and are common causes of ESKD. In addition to supportive therapy, a wide range of immunosuppressive agents are used in the management of patients with these conditions. Immunosuppression requires a careful balance of risk and benefits, and many of these agents have a narrow therapeutic window and require close monitoring. This review describes the side effects of immunosuppressive agents used in recent randomized, controlled trials of glomerular disease, and highlights some of the key adverse events that determine the choice and prescription of these medications.
- 24 July 2018
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 13 (8) , 1264-1275
Complications of Immunosuppression in Glomerular Disease
Most glomerular diseases are immunologically mediated disorders of the kidney and are common causes of ESKD. In addition to supportive therapy, a wide range of immunosuppressive agents are used in the management of patients with these conditions. Immunosuppression requires a careful balance of risk and benefits, and many of these agents have a narrow therapeutic window and require close monitoring. This review describes the side effects of immunosuppressive agents used in recent randomized, controlled trials of glomerular disease, and highlights some of the key adverse events that determine the choice and prescription of these medications.
- 1 September 2014
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 21 (5) , 408-416
The Pathogenesis of Focal Segmental Glomerulosclerosis
- 1 September 2014
- Published by Elsevier in Advances in Chronic Kidney Disease
- Vol. 21 (5) , 408-416
The Pathogenesis of Focal Segmental Glomerulosclerosis
- Open Access
- 1 August 2013
- Published by Elsevier in Kidney International
- Vol. 84 (2) , 235-238
Has the circulating permeability factor in primary FSGS been found?
- 1 August 2013
- Published by Elsevier in Kidney International
- Vol. 84 (2) , 235-238
Open AccessHas the circulating permeability factor in primary FSGS been found?
- 5 February 2013
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 9 (3) , 127-8
Glomerular disease: 'suPAR'-exciting times for FSGS.
- 5 February 2013
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 9 (3) , 127-8
Glomerular disease: 'suPAR'-exciting times for FSGS.